delirium. Delirium due to known physiological condition
Conditions
Interventions
Intervention 1: Haloperidol group: In this group, patients will receive haloperidol at a dosage of 2.5 mg intramuscularly every 6 hours a day for 7 days. Intervention 2: Escitalopram group: patients w
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All patients diagnosed with delirium by DSM5 criteria. Age over 18 years to 80 years RASS criterion greater than or equal to 3 Patients should not be in a coma for more than 24 hours and do not have a structural reason for their low level of consciousness
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Hypersensitivity to citalopram and haloperidol presence of QTC more than 440 milliseconds Having a history of taking SSRIs The presence of primary neurological disease such as stroke, dementia, psychosis Very severe cataract Presence of malignancy and severe sepsis Presence of severe metabolic disorders such as DKA and hyperosmolar coma Presence of mental disorder or disability before hospitalization Unstable vital signs Having a history of drug-requiring seizures, cardiovascular and liver disease, myasthenia gravis and thyrotoxicosis Poisoning by an unknown drug Bone marrow suppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation. Timepoint: Before the intervention, the first day to the seventh days. Method of measurement: Richmond Agitation Sedation Scale (RASS).;Illness severity. Timepoint: Before the intervention, the first day to the seventh days. Method of measurement: APACHE II Score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArefe Zeidi
Arak University of Medical Sciences
Outcome results
None listed